Topical treatment of acne vulgaris: Endolift® direct optical energy combined with LIGHTSCAN™ fractional laser
Keywords:acne, topical therapy, optical energy, Endolift®, Eufoton® LASEmaR® 1500, LIGHTSCAN™, fractional laser, non-ablative laser, laser treatment
This study evaluated the efficiency of a novel minimally invasive outpatient laser procedure, Endolift®, which destroys sebaceous glands with the combination of LASEmaR® 1500 and LIGHTSCAN™ - a fractional, non-ablative laser treatment. Thirty patients with acne vulgaris moderate to severe of both sex were treated, ranging from 18 to 35 years old; 70% had moderate and severe acne, and 30% had moderate acne. Only one session was performed of 200 microns of laser fibre inserted under the skin without anaesthesia. Eufoton® LASEmaR® 1500 works at a wavelength of 1470 nm. Three patients reported acne eruptions between 7 to 10 days after the treatment, which resolved in a few days; 70% of patients reported improvements after 3 to 4 weeks, and over time it has been going on to improve; the number of acne was significantly reduced, and the inflammation was superficial. Thirty% of patients reported improvements after 45 days. The final result is seen after 9 months; until then, we can expect gradual improvement. For 65% of the patients, one session was enough, with recommended measures to keep acne under control; for the 35%, we used 2 to 3 treatments based on LIGHTSCAN™ to keep acne under control. Patients reported a reduction in skin pores and an improvement in skin quality. There was no downtime and any side effects. In this study, patients with moderate to severe acne undergo 1 to 3 treatments based on direct optical energy reporting reduction of acne and skin inflammation.